Industry applauds funding commitment for National One Stop Shop for clinical trials


The biotechnology, medical technology and pharmaceutical industry has welcomed the announcement of $18.8 million in funding for the National One Stop Shop (NOSS) for clinical trials.

The Research and Development Taskforce (RDTF) is a collaboration between AusBiotech, Medicines Australia, and the Medical Technology Association of Australia (MTAA).

The sectors have advocated for a single, harmonised, end-to-end process across the different jurisdictions since the federal government established a Clinical Trials Action Group in 2009.

The RDTF said it is committed to working collaboratively and closely with the Government to support the platform’s development and implementation and to ensure it is built to accommodate both public and private healthcare organisations present across the nation.

Australia is a preferred destination for clinical trials. However, a complex regulatory environment for trials can act as a barrier for companies looking for efficient and cost-effective locations.

"Harmonising these processes through the NOSS will ensure patients get access to the latest medical therapies and that Australia remains globally competitive as an R&D destination, benefiting both Australian patients and the economy," said the RDTF.